Anti Mycoplasma pneumoniae activities of new quinolones, including moxifloxacin, a new compound of new quinolones and clarithromycin.
|
Accession number;00A0952099
|
| Title;Anti Mycoplasma pneumoniae activities of new quinolones, including moxifloxacin, a new compound of new quinolones and clarithromycin. |
| Author;
HAMAMOTO KUMIKO
(Kurume Univ., Fac. of Med.)
FUJIMOTO NAOYUKI
(Kurume Univ., Fac. of Med.)
ZHANG Y
(Kurume Univ., Fac. of Med.)
ARAI SUMIO
(Kurume Univ., Fac. of Med.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.9;PAGE.708-712(2000)
|
| Figure&Table&Reference;FIG.1, TBL.1, REF.17 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We tested 100 strains of Mycoplasma pneumoniae for susceptibility to moxifloxacin, a new quinolone compound, using sparfloxacin, levofloxacin, ciprofloxacin, and clarithromycin as references. Among the 100 strains of M. pneumoniae isolated from throat swabs of patients with respiratory infectious disease, 39 strains were isolated prior to 1986, 24 strains between 1986-1990, and 37 strains between 1991-1995. The susceptibility of these strains to the above antimicrobial agents was determined by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Of the new quinolones, moxifloxacin was the most active against these organisms, with MIC50 of the drug 0.08.MU.g/mL and MBC50 0.08.MU.g/mL. The MIC50s of sparfloxacin, levofloxacin, and ciprofloxacin were 0.15.MU.g/mL, 0.6.MU.g/mL, and 2.5.MU.g/mL. The MBC50s of these drugs were 0.3.MU.g/mL, 1.25 .MU.g/mL, and 2.5.MU.g/mL. The MIC50 of clarithromycin was 0.008.MU.g/mL, and the MBC50 was 0.015.MU.g/mL. These results indicate that moxifloxacin possesses a high potentiality of anti-M. pneumoniae activity and is a promising antibiotic in the treatment of mycoplasmal infections. (author abst.) |
|
|
|
Related Articles;
|
|
